Microglial inflammation eases in 80% of nonactive SPMS patients with foralumab
Most nonactive SPMS patients who took foralumab nasal spray for at least six months saw a decrease in microglial activity in their brains.| Multiple Sclerosis News Today
Most nonactive SPMS patients who took foralumab nasal spray for at least six months saw a decrease in microglial activity in their brains.| Multiple Sclerosis News Today
